Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Deferred Taxes (2019)

Historic Deferred Taxes for Allogene Therapeutics (ALLO) over the last 1 years, with Q3 2019 value amounting to $33000.0.

  • Allogene Therapeutics' Deferred Taxes changed N/A to $33000.0 in Q3 2019 from the same period last year, while for Sep 2020 it was $33000.0, marking a year-over-year change of. This contributed to the annual value of $41.9 million for FY2018, which is N/A changed from last year.
  • According to the latest figures from Q3 2019, Allogene Therapeutics' Deferred Taxes is $33000.0.
  • In the past 5 years, Allogene Therapeutics' Deferred Taxes ranged from a high of $33000.0 in Q3 2019 and a low of -$159000.0 during Q2 2019